Hormone concentrations of dominant follicles in the TALES randomized controlled trial comparing letrozole with tamoxifen.
Estradiol
Fertility preservation
Follicular fluid
Letrozole
Tamoxifen
Testosterone
Journal
Journal of assisted reproduction and genetics
ISSN: 1573-7330
Titre abrégé: J Assist Reprod Genet
Pays: Netherlands
ID NLM: 9206495
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
20
06
2022
accepted:
21
09
2022
pubmed:
4
10
2022
medline:
15
12
2022
entrez:
3
10
2022
Statut:
ppublish
Résumé
In this secondary analysis of the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) trial, we aimed to investigate if concurrent administration of letrozole vs. tamoxifen vs. no added treatment affects hormonal composition and size of stimulated ovarian follicles. TALES is a randomized controlled trial of IVF stimulation for estrogen receptor (ER)-positive breast cancer patients stimulated with gonadotropins and administered concurrent tamoxifen 20 mg or letrozole 5 mg. We analyzed estradiol (E2), testosterone (T), progesterone (P4), follicle stimulating hormone (FSH), luteinizing hormone (LH), and anti-Mullerian hormone (AMH). We used ANOVA/Kruskal-Wallis, logistic, and linear regression models to examine differences in follicular hormone levels, size, and mature oocyte yield between trial arm. We included data from total 246 follicles (94 letrozole, 82 tamoxifen, and 70 control) from 123 unique participants. E2 was lower (letrozole 187.4, tamoxifen 1026.0, control 821.5 ng/mL, p < 0.01) and T was higher (letrozole 2489, tamoxifen 571, and control 504 ng/mL, p < 0.03) in the letrozole group compared to tamoxifen and control groups, while other hormone levels and follicle size were similar across groups. There were no significant differences in hormone concentrations within the follicle between tamoxifen and control arms. On multivariate logistic regression, there was no significant association of mature oocyte yield by follicle size, hormone levels, or trial arm. Concurrent administration of letrozole with gonadotropins affects follicular E2 and T concentrations compared to tamoxifen/control. Tamoxifen was not associated with any differences in hormone concentrations within the follicle. Mature oocyte yield was similar across groups.
Sections du résumé
BACKGROUND
BACKGROUND
In this secondary analysis of the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) trial, we aimed to investigate if concurrent administration of letrozole vs. tamoxifen vs. no added treatment affects hormonal composition and size of stimulated ovarian follicles.
METHODS
METHODS
TALES is a randomized controlled trial of IVF stimulation for estrogen receptor (ER)-positive breast cancer patients stimulated with gonadotropins and administered concurrent tamoxifen 20 mg or letrozole 5 mg. We analyzed estradiol (E2), testosterone (T), progesterone (P4), follicle stimulating hormone (FSH), luteinizing hormone (LH), and anti-Mullerian hormone (AMH). We used ANOVA/Kruskal-Wallis, logistic, and linear regression models to examine differences in follicular hormone levels, size, and mature oocyte yield between trial arm.
RESULTS
RESULTS
We included data from total 246 follicles (94 letrozole, 82 tamoxifen, and 70 control) from 123 unique participants. E2 was lower (letrozole 187.4, tamoxifen 1026.0, control 821.5 ng/mL, p < 0.01) and T was higher (letrozole 2489, tamoxifen 571, and control 504 ng/mL, p < 0.03) in the letrozole group compared to tamoxifen and control groups, while other hormone levels and follicle size were similar across groups. There were no significant differences in hormone concentrations within the follicle between tamoxifen and control arms. On multivariate logistic regression, there was no significant association of mature oocyte yield by follicle size, hormone levels, or trial arm.
CONCLUSIONS
CONCLUSIONS
Concurrent administration of letrozole with gonadotropins affects follicular E2 and T concentrations compared to tamoxifen/control. Tamoxifen was not associated with any differences in hormone concentrations within the follicle. Mature oocyte yield was similar across groups.
Identifiants
pubmed: 36192617
doi: 10.1007/s10815-022-02626-6
pii: 10.1007/s10815-022-02626-6
pmc: PMC9723077
doi:
Substances chimiques
Estradiol
4TI98Z838E
Follicle Stimulating Hormone
9002-68-0
Gonadotropins
0
Letrozole
7LKK855W8I
Tamoxifen
094ZI81Y45
Types de publication
Comparative Study
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
2617-2624Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Fertil Steril. 2022 Jun;117(6):1170-1176
pubmed: 35367061
J Assist Reprod Genet. 2021 Sep;38(9):2455-2463
pubmed: 34312774
Hum Reprod. 2003 Jan;18(1):90-5
pubmed: 12525446
Reprod Sci. 2018 Jan;25(1):26-32
pubmed: 28874104
Fertil Steril. 1993 Jul;60(1):40-6
pubmed: 8513957
Exp Ther Med. 2020 Dec;20(6):131
pubmed: 33082863
J Endocr Soc. 2020 Jun 01;4(7):bvaa064
pubmed: 32666010
Fertil Steril. 2002 Feb;77(2):357-62
pubmed: 11821097
Hum Reprod. 2008 Aug;23(8):1820-9
pubmed: 18487212
J Reprod Fertil. 1987 Jul;80(2):509-16
pubmed: 3309279
Fertil Steril. 2005 Jul;84(1):82-7
pubmed: 16009161
Reprod Biol Endocrinol. 2010 Oct 11;8:117
pubmed: 20937107
Hum Reprod. 2006 Oct;21(10):2593-600
pubmed: 16785262
Hum Reprod. 2014 May;29(5):1049-57
pubmed: 24608520
Hum Reprod. 1989 Jul;4(5):584-7
pubmed: 2794018
Fertil Steril. 2008 Apr;89(4):912-21
pubmed: 17681319
Reprod Biomed Online. 2019 Jun;38(6):871-882
pubmed: 30948305
Fertil Steril. 2010 Jun;94(1):198-204
pubmed: 19361798
Fertil Steril. 1987 Dec;48(6):991-4
pubmed: 3678516
Fertil Steril. 2013 Dec;100(6):1681-5.e1
pubmed: 24055050
Reprod Biol Endocrinol. 2019 Jan 3;17(1):3
pubmed: 30606204
Reprod Biol Endocrinol. 2019 Jun 19;17(1):47
pubmed: 31217014
Fertil Steril. 1984 Jun;41(6):820-6
pubmed: 6427016
Mol Hum Reprod. 2004 Feb;10(2):77-83
pubmed: 14742691
J Clin Oncol. 2005 Jun 1;23(16):3858-9
pubmed: 15911867
Endocrinology. 1995 Nov;136(11):4951-62
pubmed: 7588229
Reprod Biomed Online. 2011 Sep;23(3):380-8
pubmed: 21782514
J Clin Oncol. 2005 Jul 1;23(19):4347-53
pubmed: 15824416
J Clin Endocrinol Metab. 1987 Apr;64(4):865-7
pubmed: 3818907
Hum Reprod. 2022 Jan 28;37(2):309-321
pubmed: 34792133
Hum Reprod. 2005 Nov;20(11):3178-83
pubmed: 16113044
J Clin Endocrinol Metab. 2016 Apr;101(4):1364-71
pubmed: 26751194
Endocrinology. 1984 Apr;114(4):1315-20
pubmed: 6546716
Fertil Steril. 2008 May;89(5 Suppl):1406-13
pubmed: 17681301
J Clin Endocrinol Metab. 1979 Apr;48(4):686-94
pubmed: 429512
J Clin Endocrinol Metab. 2007 May;92(5):1796-802
pubmed: 17327387
Fertil Steril. 2008 Mar;89(3):586-91
pubmed: 17543956
J Clin Oncol. 2008 Jun 1;26(16):2630-5
pubmed: 18509175